CTO West Coast 2026. Speak with its specialty oncology CRO team about advancing complex clinical trials. Speak with its specialty oncology CRO team about advancing complex clinical trials. Ergomed Clinical Research is a global specialty CRO supporting oncology sponsors with the delivery of complex clinical trials. At CTO West Coast 2026, its team will be available to discuss how Ergomed Group help biotech and pharma companies navigate trial complexity, strengthen execution, and advance development with confidence. From early-phase strategy to global study delivery, Ergomed Group provide flexible, tailored support for challenging oncology programs where operational precision, cross-functional coordination, and patient-focused execution matter most. Meet its experts. Its clinical development and business development team will be available for conversations throughout the event at Booth #24. Meet with Ergomed Group to discuss your upcoming oncology studies, protocol complexity, outsourcing strategy, operational planning, and delivery priorities.

Ergomed Clinical Research Named Finalist in Fierce Outsourcing Awards 2026 for "Clinical Trial Management" Raleigh, N.C., April 15, 2026 - Ergomed Clinical Research Named Finalist in "Fierce Outsourcing Awards for "Clinical Trial Management" Ergomed Clinical Research, a global CRO specializing in the most complex trials, has been named a finalist in the 2026 Fierce Outsourcing Awards in the Clinical Trial Management category. The case-based nominations were evaluated on evidence of strong trial planning, execution, and oversight, along with the ability to demonstrate clear impact on operational efficiency, patient engagement, and study outcomes. This recognition reflects the excellence of Ergomed Clinical Research's delivery in a pivotal multi-country study executed under a fixed seasonal recruitment window and limited on-site monitoring capacity. Ergomed's submission centered on a pivotal Phase III study conducted across Germany, Poland, Bulgaria, Latvia, Lithuania, and Austria. Recruitment could take place only between September and mid-February, creating one narrow execution window. Within that constraint, Ergomed successfully obtained regulatory approval for 102 sites, activated 99 of them, achieving 85% site activation within a three-month timeframe. The study screened 1,180 participants and randomized 692, exceeding the original target of 552 by 25%. Final randomization was completed ahead of plan, and dropout remained at 7.4% versus 15% anticipated. The submission also highlighted Ergomed's Operating Model, the source of excellence by design: disciplined project management, close coordination across start-up, regulatory, clinical operations, data management, biostatistics, and medical operations, RBQM-led centralized oversight, and proactive site management during peak recruitment to resolve supply, ePRO compliance, lab kit, equipment availability, and compliance issues before they slowed site performance. As data cleaning progressed toward database lock, the team closed 54,075 queries while maintaining regulatory and ethical control. "Recognition in this category matters because it reflects execution under pressure," said Natalia Grassis, Chief Clinical Research Services Officer at Ergomed. "The submitted program combined rapid activation, disciplined cross-functional delivery, proactive site support, and continuous oversight. Those are the same fundamentals biotech sponsors need when timelines are fragile and there is little room for operational drift." The operational excellence recognized in this nomination, and reflected in this submission, validates the operating model Ergomed Clinical Research brings to complex trials, particularly those in rare disease and oncology. Excellence by design is the result of realistic recruitment planning, proactive site support, and tight operational control designed to protect timelines and data quality. "This recognition as a finalist reflects the culture we've built together: one that puts patients at the heart of what we do, strives for excellence, and delivers with strong operational discipline," said Jasmina Punek, Chief People Officer, Human Resources at Ergomed Group. To learn more about the study behind this recognition, read the case study that supported Ergomed Clinical Research's nomination for the 2026 Fierce Outsourcing Awards in Clinical Trial Management. About Ergomed Clinical Research Ergomed Clinical Research turns high-stakes study plans into trials that move complex assets forward with speed, precision, and operational control. Ergomed Group is a global, full-service CRO specializing in oncology, rare disease, and other advanced therapies. As a clinical development partner to small and mid-size biotech, Ergomed Group use an agile delivery model to ensure programs start strong, with efficient site activation and patient recruitment, so trials maintain momentum in demanding development settings. Its methodology has been shaped by experience, including 500+ oncology studies, with 30,000+ patients, and 3,800+ sites globally. And its experience has taught Ergomed Group to be obsessed with what matters most: rigorous feasibility and realistic recruitment assumptions; evaluating protocols and operational strategy from the site and patient perspective; quality, transparency, and trust. This is how Ergomed Group protect sponsors' timelines and reduce risk. Media Contact: